News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
News
Closing Bell: The good news is the ASX is higher. The better news is the economy’s shot
Health & Biotech
Immutep’s clinical trials are advancing rapidly; here are the next catalysts for investors
Health & Biotech
ASX Health Stocks: Immutep shares exciting early results from Phase 2 trial on soft tissue sarcoma
News
Hot Money Monday: Expert says buying stock at 52-week high is better than ‘buy low – sell high’ strategy
News
Market Highlights: Tesla surges after Q1 update, iron ore slumps, and 5 ASX small caps to watch today
News
Closing Bell: ASX up as unemployment rate ticks higher; BHP, Nimy Resources gain
Health & Biotech
ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study
News
Market Highlights: Wall Street loses steam, the 4 biggest risks in 2024, and 5 ASX small caps to watch
Health & Biotech
ASX Health Stocks: Race Oncology gets certified for RC220; human trials next
News
Market Highlights: Oil sheds another 2pc, the most shorted stocks on ASX, and small caps to watch today
Health & Biotech
Q&A: Immutep’s CEO on improving lung cancer survival, and where to next after trial success
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: A bumper brain cancer trial and solid lithium hits
Health & Biotech
ASX Health Stocks: Chimeric leaps 65pc on Phase1A results, Immutep over 12pc on Phase 2
News
Market Highlights: Wall Street slides yet again, one mistake retirees make, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Global Health nabs Fujitsu contract, Althea generates $5.3m after property deal
News
